Work

Figure 2 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer

Year: 2025
Type: other
Abstract: Patient tumor responses in the single- and multiarm studies. A, Best overall response in the single- and multiarm studies (confirmed). In the single-arm study, data following first infusion only. One patient did not have measurable target lesions at baseline and does not appear in this plot; one patient received a transduced cell dose below the required dose level, per protocol, due to waiver granted. In the multiarm study, *arm A: one patient (M65) had unconfirmed PR. **Arm C: one patient (M1) had unequivocal progression due to new lesion and one patient died prior to first post-treatment scan and does not appear in this plot. B, Percent change from baseline in target lesion diameter in the multiarm study. Arm A patients are shown at left, and arm C is shown at right. Red circles indicate new target lesions. C, Median PFS and OS for each study. D, Radiographic images of case study patient S5, single-arm study. One patient from the single-arm study (S5) received two separate infusions, achieving best overall responses of confirmed PR from first infusion and SD from the second, per RECIST 1.1. The top left image is baseline before the first infusion, and top right is after 9 months. The bottom left image is baseline before the second infusion, and the bottom right is at week 11 after second infusion. E, Peak persistence and tumor shrinkage of case study patient S5, single-arm study. CR, complete response; LLOD, lower limit of detection; NA, not available; NE, not evaluable; PD, progressive disease; SD, stable disease.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
OpenAlex ID: W4407109402
Cites:
Cited by:
Related to: 10